| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Editorial Board
|
|
|
|
34 |
6 |
p. ii
|
artikel
|
| 2 |
First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)
|
Spreafico, A.
|
|
|
34 |
6 |
p. 520-530
|
artikel
|
| 3 |
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial
|
Gluz, O.
|
|
|
34 |
6 |
p. 531-542
|
artikel
|
| 4 |
Neoadjuvant radiochemotherapy and perioperative chemotherapy do not represent a standard at the same priority level for esophageal adenocarcinomas (with regard to ‘Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up’)
|
Cellini, F.
|
|
|
34 |
6 |
p. 553-554
|
artikel
|
| 5 |
Next generation radiotheranostics promoting precision medicine
|
Pomykala, K.L.
|
|
|
34 |
6 |
p. 507-519
|
artikel
|
| 6 |
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments
|
Ros, J.
|
|
|
34 |
6 |
p. 543-552
|
artikel
|
| 7 |
Reply to the Letter to the Editor ‘Neoadjuvant radiochemotherapy and perioperative chemotherapy does not represent a standard at same priority level for oesophageal adenocarcinomas (in regard to “Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”)’ by Cellini et al.
|
Obermannová, R.
|
|
|
34 |
6 |
p. 554-555
|
artikel
|
| 8 |
Second-line FOLFOX is not the standard of care for all patients with advanced biliary tract cancer—a commentary from the Young International Society of Geriatric Oncology
|
Liposits, G.
|
|
|
34 |
6 |
p. 555-556
|
artikel
|
| 9 |
Table of Contents
|
|
|
|
34 |
6 |
p. i
|
artikel
|
| 10 |
Translating immuno-onco-microbiome-based therapeutics: precision bugs for immune checkpoint drugs!
|
Subbiah, V.
|
|
|
34 |
6 |
p. 503-506
|
artikel
|
| 11 |
Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
|
Fizazi, K.
|
|
|
34 |
6 |
p. 557-563
|
artikel
|
Tijdschrift beschrijving